A Phase 3, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2017
At a glance
- Drugs Apremilast (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms STYLE
- Sponsors Celgene Corporation
- 12 Jul 2017 Planned End Date changed from 15 Jan 2020 to 19 Feb 2020.
- 12 Jul 2017 Planned primary completion date changed from 8 Jan 2019 to 19 Feb 2019.
- 12 Jul 2017 Status changed from not yet recruiting to recruiting.